Ser495
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser495  -  EIF4G3 (human)

Site Information
QNLNSRRsPVPAQIA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 483539

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 17 , 18 , 19 , 20 , 21 , 22 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 )
Disease tissue studied:
breast cancer ( 8 , 9 , 20 , 21 ) , breast ductal carcinoma ( 8 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 , 8 ) , cervical cancer ( 107 ) , cervical adenocarcinoma ( 107 ) , gastric cancer ( 48 , 100 , 103 , 104 , 105 , 106 ) , gastric carcinoma ( 48 , 100 , 103 , 104 , 105 , 106 ) , leukemia ( 27 , 77 ) , acute myelogenous leukemia ( 27 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 19 ) , acute megakaryoblastic leukemia (M7) ( 19 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 19 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 19 ) , acute myeloblastic leukemia, without maturation (M1) ( 19 ) , chronic lymphocytic leukemia ( 77 ) , hepatocellular carcinoma, surrounding tissue ( 102 ) , lung cancer ( 6 , 13 , 21 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 70 , 78 , 79 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 96 , 97 , 98 , 99 , 101 , 112 ) , non-small cell lung cancer ( 21 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 78 , 79 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 91 , 92 , 93 , 94 , 97 , 98 , 99 , 101 , 112 ) , non-small cell lung adenocarcinoma ( 6 , 13 , 50 , 51 , 52 , 53 , 56 , 58 , 60 , 61 , 62 , 63 , 66 , 78 , 79 ) , non-small cell large cell lung carcinoma ( 54 , 64 ) , non-small cell squamous cell lung carcinoma ( 57 , 65 , 67 ) , lymphoma ( 10 ) , B cell lymphoma ( 19 ) , Burkitt's lymphoma ( 10 ) , non-Hodgkin's lymphoma ( 19 ) , follicular lymphoma ( 10 ) , mantle cell lymphoma ( 10 ) , neuroblastoma ( 18 ) , ovarian cancer ( 8 ) , multiple myeloma ( 19 ) , melanoma skin cancer ( 5 )
Relevant cell line - cell type - tissue:
'stem, embryonic' ( 109 ) , 293 (epithelial) [ADRB1 (human), no information, overexpresses human beta1-adrenergic (ß1AR- HEK293)] ( 114 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 75 ) , 293E (epithelial) ( 49 ) , 786-O (renal) [VHL (human), transfection] ( 4 ) , 786-O (renal) ( 4 ) , A498 (renal) ( 82 ) , A549 (pulmonary) ( 14 ) , AML-193 (monocyte) ( 19 ) , BJAB (B lymphocyte) ( 10 ) , breast ( 2 , 8 ) , BT-20 (breast cell) ( 21 ) , BT-549 (breast cell) ( 21 ) , Calu 6 (pulmonary) ( 21 ) , Calu-3 (pulmonary) ( 50 ) , CL1-0 (pulmonary) ( 70 ) , CL1-1 (pulmonary) ( 70 ) , CL1-2 (pulmonary) ( 70 ) , CL1-5 (pulmonary) ( 70 ) , CMK (megakaryoblast) ( 19 ) , CTS (myeloid) ( 19 ) , DOHH2 ('B lymphocyte, precursor') ( 19 ) , DV-90 (pulmonary) ( 56 ) , FL-18 (B lymphocyte) ( 10 ) , FL-318 (B lymphocyte) ( 10 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 22 ) , Flp-In T-Rex-293 (epithelial) ( 22 ) , H2009 (pulmonary) ( 21 ) , H2077 (pulmonary) ( 21 ) , H2887 (pulmonary) ( 21 ) , H322M (pulmonary) ( 21 ) , HCC1359 (pulmonary) ( 21 ) , HCC1937 (breast cell) ( 21 ) , HCC2279 (pulmonary) ( 21 ) , HCC366 (pulmonary) ( 21 ) , HCC4006 (pulmonary) ( 21 ) , HCC78 (pulmonary) ( 21 ) , HCC827 (pulmonary) ( 21 , 78 , 79 ) , HEL (erythroid) ( 19 ) , HeLa (cervical) ( 1 , 7 , 17 , 69 , 108 , 110 , 113 , 114 , 115 , 117 , 118 ) , HeLa S3 (cervical) ( 107 ) , hepatocyte-liver ( 102 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 9 ) , HMLER ('stem, breast cancer') ( 9 ) , HOP62 (pulmonary) ( 21 ) , HUES-9 ('stem, embryonic') ( 68 ) , JEKO-1 (B lymphocyte) ( 10 ) , Jurkat (T lymphocyte) ( 15 , 24 , 25 , 26 , 71 , 95 , 111 ) , K562 (erythroid) ( 17 , 108 ) , Kasumi-1 (myeloid) ( 19 ) , KG-1 (myeloid) ( 19 , 27 ) , LCLC-103H (pulmonary) ( 21 ) , liver ( 12 ) , LOU-NH91 (squamous) ( 21 , 65 ) , lung ( 13 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 96 , 97 , 98 , 99 , 101 ) , MCF-7 (breast cell) ( 21 ) , MDA-MB-231 (breast cell) ( 21 ) , MDA-MB-468 (breast cell) ( 21 ) , MKN-45 (gastric) ( 100 , 103 , 104 , 105 , 106 ) , MV4-11 (macrophage) ( 19 ) , NB10 (neural crest) ( 18 ) , NCEB-1 (B lymphocyte) ( 10 ) , NCI-H1299 (pulmonary) ( 112 ) , NCI-H1395 (pulmonary) ( 21 ) , NCI-H1437 (pulmonary) ( 55 ) , NCI-H1563 (pulmonary) ( 53 ) , NCI-H1568 (pulmonary) ( 21 ) , NCI-H157 (pulmonary) ( 21 ) , NCI-H1648 (pulmonary) ( 21 ) , NCI-H1650 (pulmonary) ( 63 ) , NCI-H1651 (pulmonary) ( 59 ) , NCI-H1666 (pulmonary) ( 21 , 60 ) , NCI-H1944 (pulmonary) ( 51 ) , NCI-H1975 (pulmonary) ( 58 ) , NCI-H2030 (pulmonary) ( 21 ) , NCI-H2170 (squamous) ( 57 ) , NCI-H2172 (pulmonary) ( 21 ) , NCI-H2342 (pulmonary) ( 61 ) , NCI-H3122 (pulmonary) ( 52 ) , NCI-H322 (pulmonary) ( 21 ) , NCI-H441 (pulmonary) ( 62 ) , NCI-H460 (pulmonary) ( 21 , 54 ) , NCI-H520 (squamous) ( 21 , 67 ) , NCI-H647 (pulmonary) ( 21 ) , NCI-H661 (pulmonary) ( 64 ) , NCI-H838 (pulmonary) ( 66 ) , NPC (neural crest) ( 18 ) , OCI-ly1 (B lymphocyte) ( 10 ) , OPM-2 (plasma cell) ( 19 ) , ovary ( 8 ) , P31/FUJ (erythroid) ( 19 ) , PC9 (pulmonary) ( 6 , 21 ) , platelet-blood ( 116 ) , Raji (B lymphocyte) ( 10 ) , RAMOS (B lymphocyte) ( 10 ) , RL ('B lymphocyte, precursor') ( 19 ) , RPMI-8266 (plasma cell) ( 19 ) , SH-SY5Y (neural crest) [LRRK2 (human), transfection, over-expression of LRRK2(G2019S)] ( 11 ) , SH-SY5Y (neural crest) ( 11 ) , SKBr3 (breast cell) ( 20 ) , stomach ( 48 ) , SU-DHL-4 (B lymphocyte) ( 10 ) , SU-DHL-6 (B lymphocyte) ( 19 ) , U266 (plasma cell) ( 19 ) , UPN-1 (B lymphocyte) ( 10 ) , WM239A (melanocyte) ( 5 )

Upstream Regulation
Treatments:
nocodazole ( 107 )

References 

1

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

4

Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72
26506913   Curated Info

5

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

6

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

7

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

8

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

9

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

10

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

11

Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733   Curated Info

12

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

13

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

14

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

15

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

16

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

17

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

18

DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513
24349301   Curated Info

19

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

20

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

21

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

22

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

23

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

24

Mulhern D (2012) CST Curation Set: 13107; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

25

Mulhern D (2012) CST Curation Set: 13108; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

26

Mulhern D (2012) CST Curation Set: 13112; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

27

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

28

Rikova K (2011) CST Curation Set: 13113; Year: 2011; Biosample/Treatment: cell line, MGH-1/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

29

Rikova K (2011) CST Curation Set: 13114; Year: 2011; Biosample/Treatment: cell line, MGH-2/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

30

Rikova K (2011) CST Curation Set: 13115; Year: 2011; Biosample/Treatment: cell line, MGH-3/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

31

Rikova K (2011) CST Curation Set: 13116; Year: 2011; Biosample/Treatment: cell line, MGH-4/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

32

Rikova K (2011) CST Curation Set: 13117; Year: 2011; Biosample/Treatment: cell line, MGH-5/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

33

Rikova K (2011) CST Curation Set: 13118; Year: 2011; Biosample/Treatment: cell line, MGH-6/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

34

Rikova K (2011) CST Curation Set: 13119; Year: 2011; Biosample/Treatment: cell line, MGH-7/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

35

Rikova K (2011) CST Curation Set: 13120; Year: 2011; Biosample/Treatment: cell line, MGH-8/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

36

Rikova K (2011) CST Curation Set: 13121; Year: 2011; Biosample/Treatment: cell line, MGH-9/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

37

Rikova K (2011) CST Curation Set: 13122; Year: 2011; Biosample/Treatment: cell line, MGH-10/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

38

Rikova K (2011) CST Curation Set: 13123; Year: 2011; Biosample/Treatment: cell line, MGH-1/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

39

Rikova K (2011) CST Curation Set: 13124; Year: 2011; Biosample/Treatment: cell line, MGH-2/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

40

Rikova K (2011) CST Curation Set: 13125; Year: 2011; Biosample/Treatment: cell line, MGH-3/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

41

Rikova K (2011) CST Curation Set: 13126; Year: 2011; Biosample/Treatment: cell line, MGH-4/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

42

Rikova K (2011) CST Curation Set: 13127; Year: 2011; Biosample/Treatment: cell line, MGH-5/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

43

Rikova K (2011) CST Curation Set: 13128; Year: 2011; Biosample/Treatment: cell line, MGH-6/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

44

Rikova K (2011) CST Curation Set: 13129; Year: 2011; Biosample/Treatment: cell line, MGH-7/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

45

Rikova K (2011) CST Curation Set: 13130; Year: 2011; Biosample/Treatment: cell line, MGH-8/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

46

Rikova K (2011) CST Curation Set: 13131; Year: 2011; Biosample/Treatment: cell line, MGH-9/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

47

Rikova K (2011) CST Curation Set: 13132; Year: 2011; Biosample/Treatment: cell line, MGH-10/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

48

Rikova K (2011) CST Curation Set: 12177; Year: 2011; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

49

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

50

Rikova K (2011) CST Curation Set: 10887; Year: 2011; Biosample/Treatment: cell line, Calu-3/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

51

Rikova K (2011) CST Curation Set: 10919; Year: 2011; Biosample/Treatment: cell line, NCI-H1944/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

52

Rikova K (2011) CST Curation Set: 10921; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

53

Rikova K (2011) CST Curation Set: 10905; Year: 2011; Biosample/Treatment: cell line, NCI-H1563/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

54

Rikova K (2011) CST Curation Set: 10893; Year: 2011; Biosample/Treatment: cell line, NCI-H460/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

55

Rikova K (2011) CST Curation Set: 10899; Year: 2011; Biosample/Treatment: cell line, NCI-H1437/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

56

Rikova K (2011) CST Curation Set: 10895; Year: 2011; Biosample/Treatment: cell line, DV-90/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

57

Rikova K (2011) CST Curation Set: 10915; Year: 2011; Biosample/Treatment: cell line, NCI-H2170/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

58

Rikova K (2011) CST Curation Set: 10889; Year: 2011; Biosample/Treatment: cell line, NCI-H1975/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

59

Rikova K (2011) CST Curation Set: 10917; Year: 2011; Biosample/Treatment: cell line, NCI-H1651/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

60

Rikova K (2011) CST Curation Set: 10901; Year: 2011; Biosample/Treatment: cell line, NCI-H1666/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

61

Rikova K (2011) CST Curation Set: 10885; Year: 2011; Biosample/Treatment: cell line, NCI-H2342/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

62

Rikova K (2011) CST Curation Set: 10913; Year: 2011; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

63

Rikova K (2011) CST Curation Set: 10909; Year: 2011; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

64

Rikova K (2011) CST Curation Set: 10897; Year: 2011; Biosample/Treatment: cell line, NCI-H661/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

65

Rikova K (2011) CST Curation Set: 10891; Year: 2011; Biosample/Treatment: cell line, LOU-NH91/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

66

Rikova K (2011) CST Curation Set: 10883; Year: 2011; Biosample/Treatment: cell line, NCI-H838/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

67

Rikova K (2011) CST Curation Set: 10911; Year: 2011; Biosample/Treatment: cell line, NCI-H520/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

68

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

69

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

70

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info

71

Rikova K (2010) CST Curation Set: 10047; Year: 2010; Biosample/Treatment: cell line, Jurkat A/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

72

Rikova K (2010) CST Curation Set: 10043; Year: 2010; Biosample/Treatment: cell line, DFCI ERC17 serum free/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

73

Rikova K (2010) CST Curation Set: 10041; Year: 2010; Biosample/Treatment: cell line, DFCI ERC17/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

74

Rikova K (2010) CST Curation Set: 10045; Year: 2010; Biosample/Treatment: cell line, DFCI ERC17 triple/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

75

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

76

Rikova K (2010) CST Curation Set: 10037; Year: 2010; Biosample/Treatment: cell line, DFCI ERC11 serum free/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

77

Rikova K (2010) CST Curation Set: 10035; Year: 2010; Biosample/Treatment: cell line, DFCI ERC11/untreated; Disease: chronic lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

78

Rikova K (2010) CST Curation Set: 10029; Year: 2010; Biosample/Treatment: cell line, HCC827/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

79

Rikova K (2010) CST Curation Set: 10031; Year: 2010; Biosample/Treatment: cell line, HCC827/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

80

Rikova K (2010) CST Curation Set: 10039; Year: 2010; Biosample/Treatment: cell line, DFCI ERC11 triple/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

81

Rikova K (2010) CST Curation Set: 10033; Year: 2010; Biosample/Treatment: cell line, DFCI HCC827 triple/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

82

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

83

Rikova K (2010) CST Curation Set: 9763; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

84

Rikova K (2010) CST Curation Set: 9760; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

85

Rikova K (2010) CST Curation Set: 9762; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

86

Rikova K (2010) CST Curation Set: 9771; Year: 2010; Biosample/Treatment: tissue, /untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

87

Rikova K (2010) CST Curation Set: 9766; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

88

Rikova K (2010) CST Curation Set: 9769; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

89

Rikova K (2010) CST Curation Set: 9761; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

90

Rikova K (2010) CST Curation Set: 9755; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

91

Rikova K (2010) CST Curation Set: 9765; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

92

Rikova K (2010) CST Curation Set: 9756; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

93

Rikova K (2010) CST Curation Set: 9764; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

94

Rikova K (2010) CST Curation Set: 9757; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

95

Rikova K (2010) CST Curation Set: 9774; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

96

Rikova K (2010) CST Curation Set: 9770; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

97

Rikova K (2010) CST Curation Set: 9772; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

98

Rikova K (2010) CST Curation Set: 9752; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

99

Rikova K (2010) CST Curation Set: 9758; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

100

Rikova K (2010) CST Curation Set: 9773; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

101

Rikova K (2010) CST Curation Set: 9767; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

102

Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9
20166139   Curated Info

103

Possemato A (2010) CST Curation Set: 9173; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

104

Possemato A (2010) CST Curation Set: 9175; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

105

Possemato A (2010) CST Curation Set: 9174; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

106

Possemato A (2010) CST Curation Set: 9179; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

107

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

108

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

109

Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13
19664994   Curated Info

110

Chen Y, et al. (2009) Combined integrin phosphoproteomic analyses and small interfering RNA--based functional screening identify key regulators for cancer cell adhesion and migration. Cancer Res 69, 3713-20
19351860   Curated Info

111

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

112

Tsai CF, et al. (2008) Immobilized metal affinity chromatography revisited: pH/acid control toward high selectivity in phosphoproteomics. J Proteome Res 7, 4058-69
18707149   Curated Info

113

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

114

Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50
18452278   Curated Info

115

McNulty DE, Annan RS (2008) Hydrophilic interaction chromatography reduces the complexity of the phosphoproteome and improves global phosphopeptide isolation and detection. Mol Cell Proteomics 7, 971-80
18212344   Curated Info

116

Zahedi RP, et al. (2008) Phosphoproteome of resting human platelets. J Proteome Res 7, 526-34
18088087   Curated Info

117

Imami K, et al. (2008) Automated Phosphoproteome Analysis for Cultured Cancer Cells by Two-Dimensional NanoLC-MS Using a Calcined Titania/C18 Biphasic Column. Anal Sci 24, 161-6
18187866   Curated Info

118

Beausoleil SA, et al. (2006) A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol 24, 1285-92
16964243   Curated Info